249 related articles for article (PubMed ID: 22184390)
1. Impact of long-term serum platinum concentrations on neuro- and ototoxicity in Cisplatin-treated survivors of testicular cancer.
Sprauten M; Darrah TH; Peterson DR; Campbell ME; Hannigan RE; Cvancarova M; Beard C; Haugnes HS; Fosså SD; Oldenburg J; Travis LB
J Clin Oncol; 2012 Jan; 30(3):300-7. PubMed ID: 22184390
[TBL] [Abstract][Full Text] [Related]
2. Associations between long-term serum platinum and neurotoxicity and ototoxicity, endocrine gonadal function, and cardiovascular disease in testicular cancer survivors.
Hjelle LV; Bremnes RM; Gundersen POM; Sprauten M; Brydøy M; Tandstad T; Wilsgaard T; Fosså SD; Oldenburg J; Haugnes HS
Urol Oncol; 2016 Nov; 34(11):487.e13-487.e20. PubMed ID: 27523611
[TBL] [Abstract][Full Text] [Related]
3. Scale for chemotherapy-induced long-term neurotoxicity (SCIN): psychometrics, validation, and findings in a large sample of testicular cancer survivors.
Oldenburg J; Fosså SD; Dahl AA
Qual Life Res; 2006 Jun; 15(5):791-800. PubMed ID: 16721639
[TBL] [Abstract][Full Text] [Related]
4. Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors.
Brydøy M; Oldenburg J; Klepp O; Bremnes RM; Wist EA; Wentzel-Larsen T; Hauge ER; Dahl O; Fosså SD
J Natl Cancer Inst; 2009 Dec; 101(24):1682-95. PubMed ID: 19940282
[TBL] [Abstract][Full Text] [Related]
5. Long-term serum platinum changes and their association with cisplatin-related late effects in testicular cancer survivors.
Hjelle LV; Gundersen POM; Hellesnes R; Sprauten M; Brydøy M; Tandstad T; Wilsgaard T; Fosså SD; Oldenburg J; Bremnes RM; Haugnes HS
Acta Oncol; 2018 Oct; 57(10):1392-1400. PubMed ID: 29775128
[TBL] [Abstract][Full Text] [Related]
6. Long-term platinum retention after platinum-based chemotherapy in testicular cancer survivors: a 20-year follow-up study.
Hjelle LV; Gundersen PO; Oldenburg J; Brydøy M; Tandstad T; Wilsgaard T; Fosså SD; Bremnes RM; Haugnes HS
Anticancer Res; 2015 Mar; 35(3):1619-25. PubMed ID: 25750319
[TBL] [Abstract][Full Text] [Related]
7. Clinical and Genome-Wide Analysis of Serum Platinum Levels after Cisplatin-Based Chemotherapy.
Trendowski MR; El-Charif O; Ratain MJ; Monahan P; Mu Z; Wheeler HE; Dinh PC; Feldman DR; Ardeshir-Rouhani-Fard S; Hamilton RJ; Vaughn DJ; Fung C; Kollmannsberger C; Mushiroda T; Kubo M; Hannigan R; Strathmann F; Einhorn LH; Fossa SD; Travis LB; Dolan ME
Clin Cancer Res; 2019 Oct; 25(19):5913-5924. PubMed ID: 31296530
[TBL] [Abstract][Full Text] [Related]
8. Long-term exposure to circulating platinum is associated with late effects of treatment in testicular cancer survivors.
Boer H; Proost JH; Nuver J; Bunskoek S; Gietema JQ; Geubels BM; Altena R; Zwart N; Oosting SF; Vonk JM; Lefrandt JD; Uges DR; Meijer C; de Vries EG; Gietema JA
Ann Oncol; 2015 Nov; 26(11):2305-10. PubMed ID: 26347114
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin based chemotherapy in testicular cancer patients: long term platinum excretion and clinical effects.
Hohnloser JH; Schierl R; Hasford B; Emmerich B
Eur J Med Res; 1996 Sep; 1(11):509-14. PubMed ID: 9438151
[TBL] [Abstract][Full Text] [Related]
10. Long-term ototoxicity in women after cisplatin treatment for ovarian germ cell cancer.
Skalleberg J; Solheim O; Fosså SD; Småstuen MC; Osnes T; Gundersen POM; Bunne M
Gynecol Oncol; 2017 Apr; 145(1):148-153. PubMed ID: 28202195
[TBL] [Abstract][Full Text] [Related]
11. Semen and serum platinum levels in cisplatin-treated survivors of germ cell cancer.
Malone ER; Lewin J; Li X; Zhang WJ; Lau S; Jarvi K; Hamilton RJ; Hansen AR; Chen EX; Bedard PL
Cancer Med; 2022 Feb; 11(3):728-734. PubMed ID: 34918879
[TBL] [Abstract][Full Text] [Related]
12. Adsorptive voltametry to determine platinum levels in plasma from testicular cancer patients treated with cisplatin.
Gelevert T; Messerschmidt J; Meinardi MT; Alt F; Gietema JA; Franke JP; Sleijfer DT; Uges DR
Ther Drug Monit; 2001 Apr; 23(2):169-73. PubMed ID: 11294519
[TBL] [Abstract][Full Text] [Related]
13. Cumulative Burden of Morbidity Among Testicular Cancer Survivors After Standard Cisplatin-Based Chemotherapy: A Multi-Institutional Study.
Kerns SL; Fung C; Monahan PO; Ardeshir-Rouhani-Fard S; Abu Zaid MI; Williams AM; Stump TE; Sesso HD; Feldman DR; Hamilton RJ; Vaughn DJ; Beard C; Huddart RA; Kim J; Kollmannsberger C; Sahasrabudhe DM; Cook R; Fossa SD; Einhorn LH; Travis LB;
J Clin Oncol; 2018 May; 36(15):1505-1512. PubMed ID: 29617189
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and risk factors for ototoxicity after cisplatin-based chemotherapy.
Sanchez VA; Dinh PC; Rooker J; Monahan PO; Althouse SK; Fung C; Sesso HD; Einhorn LH; Dolan ME; Frisina RD; Travis LB
J Cancer Surviv; 2023 Feb; 17(1):27-39. PubMed ID: 36637632
[TBL] [Abstract][Full Text] [Related]
15. Ototoxicity After Cisplatin-Based Chemotherapy: Factors Associated With Discrepancies Between Patient-Reported Outcomes and Audiometric Assessments.
Ardeshirrouhanifard S; Fossa SD; Huddart R; Monahan PO; Fung C; Song Y; Dolan ME; Feldman DR; Hamilton RJ; Vaughn D; Martin NE; Kollmannsberger C; Dinh P; Einhorn L; Frisina RD; Travis LB
Ear Hear; 2022; 43(3):794-807. PubMed ID: 35067571
[TBL] [Abstract][Full Text] [Related]
16. Clinical and Genome-Wide Analysis of Multiple Severe Cisplatin-Induced Neurotoxicities in Adult-Onset Cancer Survivors.
Trendowski MR; Wheeler HE; El-Charif O; Feldman DR; Hamilton RJ; Vaughn DJ; Fung C; Kollmannsberger C; Einhorn LH; Travis LB; Dolan ME
Clin Cancer Res; 2020 Dec; 26(24):6550-6558. PubMed ID: 32998964
[TBL] [Abstract][Full Text] [Related]
17. Multi-Institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-Based Chemotherapy.
Fung C; Sesso HD; Williams AM; Kerns SL; Monahan P; Abu Zaid M; Feldman DR; Hamilton RJ; Vaughn DJ; Beard CJ; Kollmannsberger CK; Cook R; Althouse S; Ardeshir-Rouhani-Fard S; Lipshultz SE; Einhorn LH; Fossa SD; Travis LB;
J Clin Oncol; 2017 Apr; 35(11):1211-1222. PubMed ID: 28240972
[TBL] [Abstract][Full Text] [Related]
18. Urinary excretion of platinum in chemotherapy-treated long-term survivors of testicular cancer.
Gerl A; Schierl R
Acta Oncol; 2000; 39(4):519-22. PubMed ID: 11041115
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic yield of colonoscopy surveillance in testicular cancer survivors treated with platinum-based chemotherapy: study protocol of a prospective cross-sectional cohort study.
Ykema BLM; Bisseling TM; Spaander MCW; Moons LMG; van der Biessen-van Beek D; Saveur L; Kerst M; Mulder SF; de Wit R; Zweers D; Meijer GA; Beijnen JH; Lansdorp-Vogelaar I; van Leeuwen FE; Snaebjornsson P; van Leerdam ME
BMC Gastroenterol; 2021 Feb; 21(1):67. PubMed ID: 33579196
[TBL] [Abstract][Full Text] [Related]
20. Platinum-DNA adducts assayed in leukocytes of patients with germ cell tumors measured by atomic absorbance spectrometry and enzyme-linked immunosorbent assay.
Motzer RJ; Reed E; Perera F; Tang D; Shamkhani H; Poirier MC; Tsai WY; Parker RJ; Bosl GJ
Cancer; 1994 Jun; 73(11):2843-52. PubMed ID: 7514956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
